Therakind

What Therakind does

Therakind Limited is a UK-based specialty pharmaceutical company founded in 2006, headquartered in London. The company identifies, develops, and commercializes medicines for difficult-to-treat patient groups, with an emphasis on paediatric and geriatric populations. Therakind has successfully brought three products to market — Jylamvo (methotrexate oral solution, approved in the EU 2017 and US 2022), Buccolam (oromucosal midazolam for paediatric seizures, the first EMA Paediatric-Use Marketing Authorisation), and Ayendi (diamorphine nasal spray, MHRA fast-tracked 2015) — addressing rheumatology, oncology, dermatology, and seizure management. US rights to Jylamvo were divested to Shorla Oncology in 2023 and non-US rights to Oresund Pharma in 2024.

The company's core technology is DriDose, a proprietary dry powder intranasal drug delivery device platform acquired via exclusive licensing from Indosys Limited in September 2020. DriDose encompasses three device variants — Multi-dose Cartridge, Multi-dose Nozzle, and Unit Dose — plus a preclinical device (Nosatron). The platform enables needle-free, non-invasive drug administration that bypasses first-pass metabolism, requires no coordinated breathing, and supports thermostable formulations without cold-chain dependencies. DriDose is protected by patents granted in the US, China, Japan, and Brazil, with applications pending in additional territories.

Therakind operates a partner-centric business model spanning three revenue streams: licensing/royalty income from out-licensed commercialized products (Jylamvo to Shorla and Oresund, Buccolam to Neuraxpharm, Ayendi to Wockhardt); licensing and distribution fees from regional exclusive partners (Pharmalink in UAE, BioJam in Iberia); and co-development/professional services revenue from DriDose platform collaborations with pharmaceutical partners. The company completed a Management Buy-Out in March 2024 under CEO Dr. Susan Conroy and is investing in a pipeline of DriDose-based candidates (TKD-004 through TKD-010) spanning hypoglycaemia, vaccines, neurodegenerative disease, antimicrobials, and antiemetics. A strategic partnership with Nemera announced in April 2026 targets platform industrialisation.

Name

Therakind

Legal name

Therakind Limited

Website

https://therakind.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Therakind is a UK specialty pharmaceutical company that develops and commercializes medicines for paediatric and geriatric populations, with three approved products and a proprietary DriDose dry powder intranasal drug delivery platform serving pharmaceutical partners through licensing, distribution, and co-development arrangements.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

Keywords

• Specialty pharmaceutical products
• Dry powder nasal delivery
• Paediatric medicine development
• Drug delivery devices
• Intranasal drug administration

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Product Sales (Jylamvo®, Buccolam®, Ayendi®): Revenue from commercialized specialty pharmaceutical products addressing pediatric, geriatric, and difficult-to-treat patient populations. Products have received regulatory approvals (FDA, EMA, MHRA).
2. Out-licensing and Distribution Partnerships: Out-licensing of commercialized products (Jylamvo®) to regional distributors. US rights sold to Shorla Oncology, non-US rights sold to Oresund Pharma, distribution partnerships in UAE (Pharmalink) and Iberia (BioJam).
3. Co-development and Feasibility Studies: DriDose® platform offered for co-development with pharmaceutical partners. Proof-of-concept preclinical studies and formulation development services. Innovate UK grant funding for antiemetic development.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels1 record

Core offering

Therakind is a specialty pharmaceutical company that develops and commercializes paediatric and niche medicines, including methotrexate oral solution (Jylamvo®), oromucosal midazolam (Buccolam®), and diamorphine nasal spray (Ayendi®). The company also develops and licenses the proprietary DriDose® platform — a needle-free, dry powder intranasal drug delivery device family with single-use and reusable variants — and offers co-development and feasibility study services to pharmaceutical partners.

Product overview

Therakind is a specialty pharmaceutical company offering a portfolio of marketed medicines and an innovative drug delivery technology platform. The marketed products include Jylamvo® (methotrexate oral solution), Buccolam® (oromucosal midazolam), and Ayendi® (diamorphine nasal spray), addressing rheumatological, dermatological, oncological conditions and seizure management in paediatric patients. The proprietary DriDose® technology platform comprises dry powder nasal delivery devices including Multi-dose Cartridge, Multi-dose Nozzle, and Unit Dose variants, designed for needle-free, patient-friendly drug administration. A preclinical device called Nosatron® supports R&D applications. The pipeline includes multiple candidates (TKD-004 through TKD-010) leveraging the DriDose® platform for various therapeutic applications including hypoglycaemia, vaccines, neurodegenerative diseases, and antiemetics.

Differentiator

Problem solved

Functional benefit

Brands

• DriDose®: Innovative dry powder nasal delivery device range designed to incorporate various pharmaceutical candidates. Includes single-use and reusable versions capable of being modified for different powder-loading capacities.
• Jylamvo®
• Buccolam®
• Ayendi®
• TKD-004
• TKD-005
• TKD-006
• TKD-007
• TKD-008
• TKD-010
• TKD-009
• Buccolam®
• Ayendi®
• TKD-004
• TKD-005
• TKD-006
• TKD-007
• TKD-008

Products and services

• Jylamvo® Methotrexate 2mg/ml oral solution licensed for rheumatological, dermatological and oncological diseases in adults and children over three years old. Commercialised by Therakind's distribution partners.
• Buccolam® Oromucosal solution of buccal midazolam for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (3 months to <18 years). Marketed throughout Europe by Neuraxpharm.
• Ayendi® Diamorphine nasal spray for acute severe pain in children and adolescents (2 to 15 years). Developed and marketed by Wockhardt.
• DriDose® Multi-dose Cartridge Reusable dry powder nasal drug delivery device with disposable prefilled cartridges, allowing multiple doses and tailored powder-loading capacities. Does not require freezer or preservative; no coordinated breathing required.
• DriDose® Multi-dose Nozzle Reusable dry powder nasal device body with disposable prefilled nosepieces. Simple one-handed operation with no specialist training required; reduces plastic waste versus single-use devices.
• DriDose® Unit Dose Ready-to-use, single-use device prefilled with the appropriate drug dose for dry powder nasal delivery. Rapid onset via nasal delivery bypassing first-pass metabolism.
• Nosatron® Reusable preclinical device for nasal powder delivery to small animals. Autoclavable components, adjustable air volume and pressure, multiple nasal adaptors, and semi-automated powder filling.

Quantifiable outcome

• First oral liquid formulation of methotrexate authorized across Europe for polyarthritic juvenile idiopathic arthritis
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core, minor and regional.

• NemeracoreStrategic or Co-development Partner · 7 April 2026Strategic partnership bringing together Nemera's expertise in combination product device development and industrialisation with Therakind's experience in developing and delivering innovative medicines. DriDose® platform complements Nemera's existing liquid nasal delivery solutions, expanding their portfolio to include complete dry powder delivery capability.
• Oresund PharmacoreChannel Partner/ Reseller/ Distributor · 30 May 2024Danish specialty pharmaceutical company acquired all non-US rights to Jylamvo® for upfront payment and downstream royalties. Previously distributed Jylamvo® in Nordic countries for over three years. Expanded to serve entire European market with plans for further geographic expansion.
• Shorla OncologycoreChannel Partner/ Reseller/ Distributor · 31 October 2023US-Ireland specialty pharmaceutical company acquired US rights to Jylamvo® for oncology and autoimmune indications. FDA-approved product commercialized immediately in US market.
• Mymetics SAminorStrategic or Co-development Partner · 28 March 2023Preclinical immunogenicity study collaboration demonstrating DriDose® efficient delivery of Mymetics' SARS-CoV-2 nasal powder vaccine candidate. DriDose® delivered comparable amounts of nasal powder resulting in comparable serum antibody titres.
• Oresund PharmacoreChannel Partner/ Reseller/ Distributor · 12 May 2022Exclusive distribution partnership for Jylamvo® in Nordic countries (Sweden, Finland, Denmark, Iceland, Norway). Product successfully launched in Norway and Finland with pending launches in remaining Nordic countries.
• Indosys LimitedcoreTechnology or Integration · 1 September 2020Exclusive licensing agreement for acquisition of DriDose® intellectual property. DriDose® is an innovative dry powder nasal device platform for non-invasive, needle-free drug delivery suitable for small molecules, proteins, and peptides.
• BioJam Holding GroupregionalChannel Partner/ Reseller/ Distributor · 14 March 2020Exclusive distribution partnership for Jylamvo® in Portugal and Spain. Included successful launch announcement in Portugal.
• PharmalinkregionalChannel Partner/ Reseller/ Distributor · 9 January 2020Exclusive distribution agreement for Jylamvo® in United Arab Emirates market. Included successful launch announcement for UAE.
• WockhardtcoreChannel Partner/ Reseller/ Distributor · 1 January 2015Ayendi® (diamorphine nasal spray) developed in collaboration with Wockhardt, launched and marketed by Wockhardt since 2015 for acute severe pain in children and adolescents.
• Karolinska Institute (Iovino Group)minorStrategic or Co-development PartnerCollaboration for development of TKD-008, a novel antimicrobial candidate. Partnering on preclinical development of innovative antimicrobial treatment.

Scale indicators3 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Hovione: Specialty CDMO with strong capabilities in particle engineering, inhalation and nasal formulation, and drug-device combination products. Highly comparable to Therakind in combining formulation expertise with proprietary nasal/inhalation delivery technologies for partner drugs.
• Shorla Oncology: US-Ireland specialty oncology pharmaceutical company that acquired Jylamvo® US rights from Therakind. Comparable as a small specialty pharma focused on reformulating and commercialising oncology medicines for underserved patient populations.
• Nemera: Global drug delivery device company with a portfolio spanning nasal, ophthalmic, injectable and inhalation devices. Therakind's strategic partner for DriDose® industrialisation, and a directly comparable developer and manufacturer of nasal drug delivery devices serving large pharma customers.
• Vectura Group: Inhaled and nasal drug delivery specialist (now part of Philip Morris), with deep experience in formulation and device development for inhaled/nasal therapies. Directly comparable to Therakind's DriDose® business; Therakind's Director of Pharmaceutical Development previously led formulation at Vectura.
• Aptar Pharma: A leading global supplier of drug delivery devices including nasal spray pumps, metered dose inhalers and injectable systems. Comparable to Therakind as a device-platform company enabling nasal and pulmonary drug delivery for pharmaceutical partners.
• Neuraxpharm: European specialty pharmaceutical company focused on CNS, including paediatric neurology products such as Buccolam® (which it markets for Therakind). Directly comparable as a European specialty pharma peer with overlapping paediatric CNS franchise.
• Owen Mumford: Medical device company specialising in injectable drug delivery (auto-injectors, pen injectors, syringes) and is also developing needle-free and nasal delivery platforms. Therakind's Device Consultant Chris Townsend previously led Owen Mumford programmes, and Owen Mumford is directly comparable as a device-led drug delivery peer.

Broad incumbents

• West Pharmaceutical Services: Major global manufacturer of drug delivery and containment components, including elastomeric closures and innovative delivery devices. Comparable to Therakind as a broader incumbent in the drug delivery device space with overlapping nasal, inhalation and injectable capabilities.
• Catalent: Large global CDMO with deep capabilities in oral, inhaled and nasal drug delivery, including device-integration services for partners. Comparable to Therakind as a broader pharma services and drug delivery platform player with overlapping nasal delivery expertise.

Emerging players

• Halo Pharma: Specialty pharmaceutical CDMO focused on small-batch commercial manufacturing for niche and paediatric products, including oral liquids and other difficult-to-formulate dosage forms. Comparable to Therakind's specialty pharma formulation and small-scale commercial manufacturing orientation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Therakind
• LinkedInlinkedin.com/company/therakind

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Therakind